{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T19:39:39Z","timestamp":1768678779445,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dyslipidemia is a frequent side effect associated with nilotinib treatment. Patients with chronic myeloid leukemia (CML) under treatment with nilotinib who develop dyslipidemia have been shown to have a higher risk of presenting atherosclerotic cardiovascular disease (ACVD). Therapeutic discontinuation in selected individuals could be a strategy in order to prevent the development of ACVD. Observational study of patients with CML under nilotinib treatment. The lipid values were gathered before starting with nilotinib and after 3 months. Such values were also measured before discontinuation in patients who suspended nilotinib treatment, as well as 3 and 12\u00a0months later. 32 patients were included, 19 of them treated in monotherapy with nilotinib. The concentrations of total cholesterol and low-density lipoproteins (LDL) increased significantly after 3\u00a0months of treatment (27.29\u00a0mg\/dL\u2009\u00b1\u200922.88, p\u2009&lt;\u20090.01). Of the total number of patients treated, 12 discontinued the treatment. LDL concentration was significantly reduced after 3\u00a0months of the nilotinib discontinuation (\u2212\u200927.58\u00a0mg\/dL\u2009\u00b1\u200938.30, p\u2009=\u20090.030), remaining substantially lower after 12\u00a0months, compared to the time previous to discontinuation (\u2212\u200924.58\u00a0mg\/dL\u2009\u00b1\u200937.31, p\u2009=\u20090.043). Nilotinib suspension reduces significantly LDL concentrations. These data support the strategy of therapeutic discontinuation in order to prevent future cardiovascular complications, especially in patients with prior cardiovascular risk factors.<\/jats:p>","DOI":"10.1038\/s41598-023-39057-x","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T10:01:30Z","timestamp":1689933690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation"],"prefix":"10.1038","volume":"13","author":[{"given":"Ricardo","family":"Roa-Chamorro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Puerta-Puerta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Torres-Quintero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Ja\u00e9n-\u00c1guila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Gonz\u00e1lez-Bustos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Rodr\u00edguez-Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Diego","family":"Mediavilla-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"issue":"24","key":"39057_CR1","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower, H. et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J. Clin. Oncol. 34(24), 2851\u20132857 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"39057_CR2","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus, A. et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30(5), 1044\u20131054 (2016).","journal-title":"Leukemia"},{"issue":"7","key":"39057_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajh.22037","volume":"86","author":"KJ Aichberger","year":"2011","unstructured":"Aichberger, K. J. et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am. J. Hematol. 86(7), 533\u2013539 (2011).","journal-title":"Am. J. Hematol."},{"issue":"44","key":"39057_CR4","doi-asserted-by":"publisher","first-page":"72311","DOI":"10.18632\/oncotarget.11100","volume":"7","author":"M Bocchia","year":"2016","unstructured":"Bocchia, M. et al. Genetic predisposition and induced pro-inflammatory\/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. Oncotarget 7(44), 72311\u201372321 (2016).","journal-title":"Oncotarget"},{"issue":"4","key":"39057_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s11523-016-0417-x","volume":"11","author":"E Bondon-Guitton","year":"2016","unstructured":"Bondon-Guitton, E. et al. Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy. Target Oncol. 11(4), 549\u2013552 (2016).","journal-title":"Target Oncol."},{"issue":"6","key":"39057_CR6","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","volume":"57","author":"C Chai-Adisaksopha","year":"2016","unstructured":"Chai-Adisaksopha, C., Lam, W. & Hillis, C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A meta-analysis. Leuk. Lymphoma 57(6), 1300\u20131310 (2016).","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"39057_CR7","doi-asserted-by":"publisher","first-page":"E159","DOI":"10.1002\/ajh.25102","volume":"93","author":"G Caocci","year":"2018","unstructured":"Caocci, G. et al. Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. Am. J. Hematol. 93(7), E159\u2013E161 (2018).","journal-title":"Am. J. Hematol."},{"issue":"3","key":"39057_CR8","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/ehf2.13897","volume":"9","author":"D Di Lisi","year":"2022","unstructured":"Di Lisi, D. et al. The new HFA\/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity. ESC Heart Fail. 9(3), 1914\u20131919 (2022).","journal-title":"ESC Heart Fail."},{"key":"39057_CR9","unstructured":"Linton, M. F. et al. The Role of Lipids and Lipoproteins in Atherosclerosis. Endotext. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK343489\/ (Accessed 21 December 2022) (MDText.com, Inc., 2019)."},{"issue":"5","key":"39057_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","volume":"27","author":"J Bor\u00e9n","year":"2016","unstructured":"Bor\u00e9n, J. & Williams, K. J. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: A triumph of simplicity. Curr. Opin. Lipidol. 27(5), 473\u2013483 (2016).","journal-title":"Curr. Opin. Lipidol."},{"issue":"8","key":"39057_CR11","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s00277-020-04392-w","volume":"100","author":"G Caocci","year":"2021","unstructured":"Caocci, G. et al. Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. Ann. Hematol. 100(8), 2005\u20132014 (2021).","journal-title":"Ann. Hematol."},{"issue":"5","key":"39057_CR12","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","volume":"35","author":"JP Radich","year":"2021","unstructured":"Radich, J. P. et al. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia 35(5), 1344\u20131355 (2021).","journal-title":"Leukemia"},{"key":"39057_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","volume":"316","author":"AP Singh","year":"2020","unstructured":"Singh, A. P., Umbarkar, P., Tousif, S. & Lal, H. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib. Int. J. Cardiol. 316, 214\u2013221 (2020).","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"39057_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/jcpt.13294","volume":"46","author":"M Abumiya","year":"2021","unstructured":"Abumiya, M. et al. Effects of proprotein convertase subtilisin\/kexin type 9 and nilotinib plasma concentrations on nilotinib-induced hypercholesterolaemia in patients with chronic myeloid leukaemia. J. Clin. Pharm. Ther. 46(2), 382\u2013387 (2021).","journal-title":"J. Clin. Pharm. Ther."},{"key":"39057_CR15","doi-asserted-by":"publisher","first-page":"835563","DOI":"10.3389\/fonc.2022.835563","volume":"12","author":"A Sicuranza","year":"2022","unstructured":"Sicuranza, A. et al. Pro-inflammatory and pro-oxidative changes during nilotinib treatment in CML patients: Results of a prospective multicenter front-line TKIs study (KIARO study). Front. Oncol. 12, 835563 (2022).","journal-title":"Front. Oncol."},{"key":"39057_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.thromres.2016.07.019","volume":"145","author":"N Alhawiti","year":"2016","unstructured":"Alhawiti, N. et al. The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb. Res. 145, 54\u201364 (2016).","journal-title":"Thromb. Res."},{"key":"39057_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fcvm.2018.00055","volume":"5","author":"MG Pouwer","year":"2018","unstructured":"Pouwer, M. G. et al. The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model. Front. Cardiovasc. Med. 5, 55 (2018).","journal-title":"Front. Cardiovasc. Med."},{"issue":"3","key":"39057_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne, G. et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J. Clin. Oncol. 35(3), 298\u2013305 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"39057_CR19","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1080\/10428194.2018.1535114","volume":"60","author":"EK Ritchie","year":"2019","unstructured":"Ritchie, E. K. Differentiating factors in treatment-free remission trials: Impact of study design on results and clinical applications. Leuk. Lymphoma 60(5), 1116\u20131125 (2019).","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"39057_CR20","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea, D. et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: Interim analysis of the STOP 2G-TKI study. Blood 129(7), 846\u2013854 (2017).","journal-title":"Blood"},{"issue":"6","key":"39057_CR21","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele, S. et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 19(6), 747\u2013757 (2018).","journal-title":"Lancet Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39057-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39057-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39057-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T10:05:57Z","timestamp":1689933957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39057-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["39057"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-39057-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"30 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11781"}}